Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Granules India Ltd

| Quarterly Financial Results Q3 FY 2025-26

NEUTRAL SENTIMENT

Report Source

⬤23rd Jan 26

Summary : Granules India reported strong Q3/9M FY26 results, with revenue and profit growth, despite USFDA challenges and ongoing remediation efforts, while also pursuing strategic acquisitions and capital raising for future expansion.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Major expenses include cost of materials consumed, employee benefits, finance costs, depreciation, and other expenses.
  2. Standalone Q3 FY26 Revenue from operations: Rs. 8,953.18 million.
  3. Consolidated Q3 FY26 Revenue from operations: Rs. 13,879.40 million.
  4. Revenue primarily from sale of products and other operating revenue.
  5. Previously disclosed contingent liabilities for Granules Pharmaceuticals Inc. litigations.
  6. Standalone Paid-up equity share capital: Rs. 242.67 million (as of Dec 31, 2025).
  7. Consolidated Paid-up equity share capital: Rs. 242.67 million (as of Dec 31, 2025).
  8. Consolidated Other equity: Rs. 36,913.24 million (as of Mar 31, 2025).
  9. Both standalone and consolidated unaudited financial results are presented.
  10. Consolidated results include Granules India Limited and its subsidiaries.

Corporate Overview

  1. India (Granules India Limited, Granules Life Sciences Private Limited, Granules CZRO Private Limited, Ascelis Peptides Private Limited)
  2. United States of America (Granules Pharmaceuticals Inc., Granules Consumer Health LLC)
  3. Switzerland (Senn Chemicals AG)
  4. Germany (Granules Pharmaceuticals GMBH)
  5. Canada (Granules Pharmaceuticals Canada, Inc.)
  6. USFDA warning letter for Gagillapur facility in February 2025.
  7. Voluntarily paused manufacturing and distribution at Gagillapur facility.
  8. Impacted revenue due to production slowdown.
  9. Increased expenses from consultancy and air freight costs for remediation.
  10. Settlements of ongoing litigations for Granules Pharmaceuticals Inc.
  11. Operates in pharmaceutical products, including ingredients and intermediaries.
  12. Pharmaceutical products, ingredients, and intermediaries.
  13. Gagillapur facility paused manufacturing due to USFDA warning letter.
  14. Acquired 100% equity stake in Senn Chemicals AG, Switzerland.
  15. Acquired 100% equity stake in Granules Pharmaceuticals GmbH, Germany.
  16. Incorporated new subsidiary Granules Pharmaceuticals Canada, Inc.
  17. Approved capital raising of up to Rs. 14,625.00 million via convertible warrants.
  18. Approved capital raising of up to Rs. 3,000.00 million via fully paid-equity shares.

Risk Factors

  1. USFDA warning letter impacts production.
  2. Increased expenses from remediation efforts.
  3. Ongoing litigations create uncertainty.
  4. Regulatory changes could impact operations.

Key Drivers

  1. Strong revenue growth year-on-year.
  2. Approved capital raising for expansion.
  3. Strategic acquisitions completed recently.
  4. Remediation plan for USFDA facility.

Auditor’s Report

  1. Limited Review Report (not an audit opinion).
  2. No material misstatement found in the unaudited financial results.

Board Commentary

  1. USFDA warning letter for Gagillapur facility.
  2. Transaction costs related to acquisition of Senn Chemicals AG.
  3. Settlements of ongoing litigations for Granules Pharmaceuticals Inc.
  4. USFDA warning letter for Gagillapur facility in February 2025.
  5. Settlements of certain ongoing litigations of Granules Pharmaceuticals Inc.
  6. Acquisition of Senn Chemicals AG, Switzerland.
  7. Acquisition of Granules Pharmaceuticals GmbH, Germany.
  8. Capital raising through convertible warrants and equity shares.

Corporate Governance

  1. Audit Committee reviewed the unaudited financial results.

Management Discussion & Analysis

Future Strategy

  1. Initiated remediation plan for Gagillapur facility with independent consultants.
  2. Enhancing existing procedures and implementing new procedures at Gagillapur.
  3. Engaging consultants for data collection and review for corrective actions.
  4. Capital raising through warrants and equity shares for future growth.

Operational Focus Areas

  1. Addressing USFDA observations at Gagillapur facility.
  2. Conducting comprehensive risk assessments.
  3. Implementing corrective and preventive actions for regulatory compliance.

Performance Drivers

  1. Increased revenue from operations for the quarter and nine months ended December 31, 2025 (Standalone and Consolidated).
  2. Growth in profit for the period for the quarter and nine months ended December 31, 2025 (Standalone and Consolidated).

Risk Control Measures

  1. Voluntarily paused manufacturing to address USFDA observations.
  2. Engaged independent consultants for remediation plan.
  3. Evaluating impact of new labour codes for appropriate accounting treatment.

Critical Risks

  1. USFDA warning letter for Gagillapur facility.
  2. Slowdown in production and distribution due to regulatory issues.
  3. Increased operational expenses (consultancy, air freight).
  4. Uncertainty regarding outcome of ongoing litigations.
Granules India Ltd (GRANULES) Quarterly Report Analysis & Insights | Dhanarthi